Open AccessParvovirus B19‐induced anemia in renal transplantation: a role for rHuEPO in resistance to classical treatment
Author(s) -
Arzouk Nadia,
Snanoudj Renaud,
BeauchampNicoud Anne,
Mourad Georges,
Charpentier Bernard,
Tchernia Gil,
Durrbach Antoine
Publication year - 2006
Publication title -
transplant international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.998
H-Index - 82
eISSN - 1432-2277
pISSN - 0934-0874
DOI - 10.1111/j.1432-2277.2005.00247.x
Subject(s) - medicine , parvovirus , erythropoietin , immunosuppression , pure red cell aplasia , anemia , discontinuation , transplantation , immunology , virus
Summary Human parvovirus B19 (PVB 19) is responsible for pure red cell aplasia in immunocompromised patients, and particularly solid organ recipients. Intravenous immunoglobulins (IVIG) have been shown to be efficient to achieve the correction of anemia in association with the reduction of immunosuppression. We report a case of kidney transplant recipient with PVB 19‐induced anemia that did not respond to recombinant human erythropoietin (rHuEPO) and to a first course of IVIG. After discontinuation of rHuEPO, a second course of IVIG was successful with the resolution of anemia. We discuss the role of rHuEPO that may facilitate PVB 19 replication in erythropoietin‐sensitive human erythroid progenitor cells.